Orphan drug profits windfall tax
Rep. Stark's (D-Calif.) HR 3551 would permit orphan drug makers to recoup only 100% of the R&D costs plus a 25% annual profit during market exclusivity. "The Pink Sheet" incorrectly said the bill would permit manufacturers to recoup twice their investment (Oct. 21, p. 2); Stark's earlier bill (HR 1713) would have permitted the higher amount....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth